Esperion notched major back-to-back FDA wins in February with its cholesterol-busting duo Nexlitol and Nexlizet. Now, with physicians largely unfamiliar with the drugs, the company is hoping new clinical data will help build confidence as both prepare to hit the market.
In multiple phase 3 trials, Esperion’s Nexletol significantly lowered levels of high-sensitivity C-reactive protein in patients with abnormally high triglyceride levels whether they were actively taking standard-of-care statins or not, according to a pooled data analysis presented Saturday at the American College of Cardiology scientific sessions.
In patients whose protein levels measured above a baseline marker––a sign of inflammation––Nexletol lowered those levels by 42% at 12 weeks, Esperion said in a release. Nexletol significantly cut those levels whether or not patients were taking statins and regardless of the intensity of statins they received.
Veeva 2020 Unified Clinical Operations Survey
We believe you have the knowledge and expertise to make this year’s Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.
In a separate analysis, Nexletol significantly lowered levels of LDL-C and other lipids regardless of whether patients were treated with a drug alongside cholesterol buster ezitimibe.
The new analyses may help prescribers grow more comfortable with soon-to-hit-the-market Nexletol, a cholesterol fighter that nabbed an FDA approval in late February to lower LDL-C levels in patients with abnormally high cholesterol levels or an established CV disease who had reached maximum statin tolerance. The drug is expected to start distribution March 30.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.